Chimeric antigen receptor T cell (Car-T) therapies are transformative therapeutics that are highly effective in treating relapsed and refractory B cell malignancies. Car-T products directed against CD19 are now approved internationally for B cell acute lymphoblastic leukaemia, Aggressive lymphoma (D...
Speaker